Predictive value of CA 125 in detection of ovarian cancer in pre- and postmenopausal patients;Wartość predykcyjna stężenia CA 125 w diagnostyce raka jajnika u kobiet przed i po menopauzie

Ginekologia Polska

Volumn 81, Issue 7, 2010, Pages 511-515

  Wojciech, Grzybowski ^a   Jarosław, Beta ^a   Anna, Fritz ^a   Andrzej, Durczyński ^a   Mariusz, Bidziński ^c   Marek, Grabiec ^d   Jakimiuk, Artur J ^a,b  

^a Centralny Szpital Kliniczny Ministerstwa Spraw Wewn trznych   (Poland)

^b Zaklad Zdrowia Prokreacyjnego IMiD   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Biomarkers; CA 125; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; POLAND; POSTMENOPAUSE; PREDICTION AND FORECASTING; PREMENOPAUSE; SENSITIVITY AND SPECIFICITY;

ADULT; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLAND; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77958158668     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hoskins W. Prospective on ovarian cancer: why prevent? J Cell Biochem Suppl. 1995, 23, 189-199.
2. Tortolero-Luna G, Mitchell M. The epidemiology of ovarian cancer. J Cell Biochem Suppl 1995, 23, 200-207.
3. Zarcone R, Bellini P, Carfora E, [et al.]. Role of ultrasonography in the early diagnosis of ovarian cancer. Eur J Gynaecol Oncol. 1997, 18, 418-419.
4. Didkowska J, Wojciechowska U, Tarkowski W, [i wsp.]. Nowotwory złośliwe w Polsce w 2000 roku. Warszawa: Centrum Onkologii - Instytut, 2003.
5. Markowska J. Onkologia Ginekologiczna. Wrocław: Urban & Partner, 2002.
6. Chu C, Rubin S. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol. 2006, 20, 307-320.
7. Annual Report on the results of treatment in gynecological cancer. Statements of results obtained in patients treated in 1987 to 1989, inclusive actuarial survival up to 1993. Twenty-second volume. 83, 226.
8. Wolfe C, Tilling K, Raju K. Management and survival of ovarian cancer patients in south east England. Eur J Cancer. 1997, 33, 1835-1840.
9. Patridge G, Philips J, Menck H, [et al.]. The National Cancer Date Base Report on Ovarian Cancer Treatment in United States Hospitals. Cancer. 1996, 78, 2236-2246.
10. Bast R Jr, Knapp R. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 1985, 19, 354-356.
11. Fishman D. The present and future of biomarkers for the early detection of epithelial ovarian carcinoma. In: Prognostic factors in epithelial ovarian carcinoma. Ed. Bösze P. CME J Gynecol Oncol. 1999, Chapter 13, 4, 1, 33-6.
12. Jacobs I, Bast R Jr. The CA 125 tumour-associated antigen: a review of literature. Human Reprod. 1989, 4, 1-12.
13. Woolas R, Xu F, Jacobs I, [et al.]. Elevation of multiple serum markers in patients with stage I ovarian cancer. Natl Cancer Inst. 1993, 85, 1748-1751.
14. Rosenthal A, Jacobs I. Ovarian cancer screening. Semin Oncol. 1998, 25, 315-325. Review. Erratum in: Semin Oncol. 1998, 25(6), 707.
15. Nguyen H, Averette H, Hoskins W, [et al.]. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer. 1993, 15, 72, 3007-3011.
16. Bast R, Brewer M, Zou C, [et al.]. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 2007, 174, 91-100.
17. Bast R Jr., Knapp R. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 1985, 19, 354-356.
18. Scholler N, Garvik B, Hayden-Ledbetter M. Development of a CA 125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett. 2007, 247, 130-136.
19. Rapkiewicz A, Espina V, Petricoin E 3rd, [et al.]. Biomarkers of ovarian tumours Eur J Cancer. 2004, 40, 2604-2612.
20. Rosen D, Wang L, Atkinson J, [et al.]. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005, 99, 267-277.
21. Rustin G, Nelstrop A, Tuxen M, [et al.]. Defining progression of ovarian carcinoma during followup according to CA-125: a North Thames Ovary Group study. Ann Oncol. 1996, 7, 361-364.
22. Granberg S, Wikland M, Friberg L. Tumor marker CA 125 level and ovarian volume at diffrent cycle day periods and in postmenopause. Int J Gynecol Obstet. 1990, 33, 149-152.
23. Pauler D, Menon U, McIntosh M, [et al.]. Factors influencing serum CA 125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2001, 10, 489-493.
24. Malkasian G Jr, Knapp R, Lavin P, [et al.]. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant dissease. Am J Obstet Gynecol. 1988, 159, 341-346.